Related Experiment Video
Updated: Sep 24, 2025

Assessment of Perigenital Sensitivity and Prostatic Mast Cell Activation in a Mouse Model of Neonatal Maternal Separation
Published on: August 13, 2015
[Cystic diseases in urology : Recommendations for patients with systemic mast cell disease]
H E Knüpfer1, V Keppler2, T Zienkiewicz3
1Urologische Praxis, Rochusstraße 289, 53123, Bonn, Deutschland.
Abstract:
The systemic mast cell disease (MCAD; prevalence 17%) may occur frequently in urological patients. MCAD-induced changes include cysts in all organs, also in the urogenital system. In the presence of MCAD, the surgical removal of such cysts must consider specific features of the MCAD in order to reduce surgical and complication risks. Vice versa, if in urological examinations multiple cysts are found, this could be an indication of a possibly existing, in some circumstances, unrecognized MCAD.
Related Concept Videos
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Cystic Fibrosis: Management
Sinus disease and chronic...
Urinary Tract Calculi III: Medical Management
Urologic Endoscopic Procedure: Cystoscopic Examination
Nephrotic Syndrome II : Assessment and Medical Management
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

